DAS28 remission and clinical efficacy in rheumatoid arthritis patients with inadequate responses to methotrexate treated with abatacept: The Phase III AIM trial and a Phase IIB trial long-term extension

被引：0
|
作者：
Westhovens, R
Kremer, J
Shergy, W
Abud-Mendoza, C
Aranda, R
Becker, JC
Zhou, Y
Mokliatchouk, O
Dougados, M
机构：
[1] Univ Hosp Gasthuisberg, Louvain, Belgium
[2] Ctr Rheumatol, Albany, NY USA
[3] Albany Med Coll, Albany, NY 12208 USA
[4] Rheumatol Assoc N Alabama, Huntsville, AL USA
[5] Hosp Cent Ignac Morones Prieto, San Luis Potosi, Mexico
[6] Bristol Myers Squibb Co, Princeton, NJ USA
[7] Hosp Cochin, Paris, France
来源：
ARTHRITIS AND RHEUMATISM | 2005年 / 52卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S142 / S142
页数：1
相关论文
共 50 条
  • [21] Das28 responses in patients with active rheumatoid arthritis who received golimumab and methotrexate: A randomized, double-blind, placebo-controlled phase 2 trial
    Kay, J.
    Matteson, E. L.
    Dasgupta, B.
    Nash, P.
    Durezs, P.
    Hall, S.
    Han, J.
    Rahman, M. U.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 323 - 323
  • [22] Long-term efficacy, remission, and safety of adalimumab (HUMIRA®) plus methotrexate in patients with rheumatoid arthritis in the ARMADA trial.
    Weinblatt, ME
    Keystone, EC
    Furst, DE
    Kavanaugh, AF
    Chartash, EK
    Segurado, OG
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S563 - S563
  • [23] Abatacept (Aba) provides long-term efficacy and significant sustained benefits in clinical and patient (Pt)-reported outcomes (PROs) through 2 yrs in rheumatoid arthritis (RA) pts with an inadequate response to Methotrexate (MTX): The long-term extension (LTE) of the aim BA in inadequate responders to MTX) trial
    Emery, P.
    Russell, A.
    Becker, J. C.
    Aranda, R.
    Li, T.
    Teng, J.
    Schmidely, N.
    LeBars, M.
    Moreland, L. W.
    Westhovens, R.
    Kremer, J. M.
    RHEUMATOLOGY, 2007, 46 : I40 - I40
  • [24] Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study
    Westhovens, R.
    Kremer, J. M.
    Emery, P.
    Russell, A. S.
    Alten, R.
    Barre, E.
    Dougados, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (04) : 553 - 562
  • [25] Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial
    Vibeke Strand
    Mark Kosinski
    Chieh-I Chen
    George Joseph
    Regina Rendas-Baum
    Neil M. H. Graham
    Hubert van Hoogstraten
    Martha Bayliss
    Chunpeng Fan
    Tom Huizinga
    Mark C. Genovese
    Arthritis Research & Therapy, 18
  • [26] Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial
    Strand, Vibeke
    Kosinski, Mark
    Chen, Chieh-I
    Joseph, George
    Rendas-Baum, Regina
    Graham, Neil M. H.
    van Hoogstraten, Hubert
    Bayliss, Martha
    Fan, Chunpeng
    Huizinga, Tom
    Genovese, Mark C.
    ARTHRITIS RESEARCH & THERAPY, 2016, 18
  • [27] Sustained improvements in disease activity score 28 (DAS28) and patient (PT)-reported outcomes (PRO) with abatacept (ABA) in rheumatoid arthritis (RA) pts with an inadequate response to anti-TNF therapy: The long-term extension (LTE) of the attain trial
    Sibilia, J.
    Schiff, M.
    Genovese, M. C.
    Becker, J. P.
    Li, T.
    McCann, T.
    Dougados, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 501 - 501
  • [28] Discontinuation of Methotrexate or Glucocorticoids in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Clinical Efficacy Data from Long-Term Extension Studies
    Fleischmann, Roy
    Wollenhaupt, Juergen
    Cohen, Stanley
    Weinblatt, Michael
    Wang, Lisy
    Fan, Haiyun
    Andrews, John
    Takiya, Liza
    Bananis, Eustratios
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [29] Clinical benefits of donepezil: Results from a long-term phase III extension trial
    Doody, RS
    Pratt, RD
    Perdomo, CA
    NEUROLOGY, 1999, 52 (06) : A174 - A174
  • [30] CLINICAL OUTCOMES UP TO WEEK 48 OF FILGOTINIB TREATMENT IN AN ONGOING LONG-TERM EXTENSION TRIAL OF RA PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE INITIALLY TREATED WITH FILGOTINIB OR ADALIMUMAB DURING THE PHASE 3 PARENT TRIAL
    Combe, Bernard
    Tanaka, Yoshiya
    Emery, Paul
    Pechonkina, Alena
    Kuo, Albert
    Gong, Qi
    Van Beneden, Katrien
    Rajendran, Vijay
    Schulze-Koops, Hendrik
    RHEUMATOLOGY, 2022, 61
12345